Assessing Major Adverse Liver Outcomes With Baclofen Compared to Acamprosate in Compensated Alcohol-Associated Cirrhosis - PubMed
5 hours ago
- #baclofen
- #acamprosate
- #alcohol-associated cirrhosis
- Study compares safety of baclofen vs. acamprosate in alcohol-associated cirrhosis patients.
- Baclofen showed higher 1-year incidence of major adverse liver outcomes (34.3%) compared to acamprosate (27.4%).
- Hazard ratio for major adverse liver outcomes was 1.32 (95% CI, 1.02-1.70) favoring acamprosate.
- Baclofen specifically increased risk of hepatic encephalopathy (HR 1.80; 95% CI, 1.21-2.69).
- No significant differences found in other decompensation events or mortality between the two drugs.
- Subgroup analysis indicated higher risk in patients aged 56-70 years with baclofen.
- Conclusion: Baclofen poses greater risk of hepatic encephalopathy than acamprosate in this patient group.